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T he efficacy of antiarrhythmic agents in patients with cardiovascular disease is currently being re- evaluated in the light of new cliical data.* Al- 
though these drugs are effective in suppressing ventricu- 
lar arrhythmias, they have not been shown to prolong 
life in a randomized controlled trial. The recent reports 
of the Cardiac Arrhythmia Suppression Trial indicate 
that certain drugs may actually be associated with an 
accelerated mortality despite their ability to suppress 
ventricular ectopy. Victims resuscitated after out-of- 
hospital cardiac arrest are known to be at an increased 
risk of another cardiac arrest. Frequent ventricular ec- 
topy is known to be a characteristic of these patients,2J 
and it is presumed that treatment with antiarrhythmic 
agents may have a salutary effect on their mortality 
rate. Several studies in patients with frequent ventricu- 
lar ectopy using a variety of antiarrhythmic agents with 
and without electrophysiologic guidance report a de- 
crease in mortality rate when compared to historical 
controls.4-6 
. 
In a previous report by us, the most significant clini- 
cal predictor of total mortality in this group of resusci- 
tated out-of-hospital survivors was a history of digoxin 
therapy; for sudden death it was quinidine therapym3 
Frequent and repetitive ventricular ectopy was also 
demonstrated to be predictive of total mortality in this 
population7 The increased mortality rate associated 
with digoxin and quinidine therapy was thought to be 
due either to the adverse effect of the drugs or to the 
presence of heart failure for which digoxin therapy 
could be considered a surrogate. This study retrospec- 
tively compares the effect of empiric therapy with quini- 
dine, procainamide or placebo, with and without con- 
current digoxin therapy, on survival in patients who 
have been resuscitated after an out-of-hospital cardiac 
arrest. 
METHOD6 
This is a retrospective analysis of the effect of empir- 
ic antiarrhythmic therapy in previously reported pa- 
tients resuscitated after out-of-hospital cardiac arrest3 
from July 1, 1975, through June 30, 1982. Informed 
consent was obtained and eligible patients were regis- 
tered. Laboratory and electrocardiographic data were 
collected. Hospital and Emergency Medical Service 
records were reviewed for clinical information relating 
to medical history. Because study ambulatory electro- 
cardiographic data were not available at the time of dis- 
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charge or at any time during the follow-up, the medical 
management of patients in regard to treatment of car- 
diac failure and arrhythmias was determined by each 
patient’s private physician without regard to this 
information. 
The patients were classified using previously de- 
scribed methodology.3 Of the 274 patients successfully 
resuscitated, 227 (83%) were classified as having signifi- 
cant coronary heart disease, based on the presence of a 
previous myocardial infarction, angina pectoris or coro- 
nary angiographic evidence of significant coronary arte- 
rial obstruction. Of these 227 patients, complete data 
regarding digoxin and antiarrhythmic drug therapy 
were available in 209 (76%) patients. This group of 209 
patients is the population analyzed in this study. Eighty- 
six (41%) of these patients were classified as having 
an acute myocardial infarction, 79 (38%) an ischemic 
event and 44 (21%) primary arrhythmic events. Patients 
were interviewed by the study nurse 2 months after dis- 
charge, and every 4 months thereafter. After each visit 
the clinical status of the patient was evaluated and com- 
pliance for all medication was established. 
Death within 1 hour of new or accelerating symp- 
toms was classified as sudden death. The follow-up peri- 
od ranged from a minimum of 6 months to a maximum 
of 93 months with an average of 35 months. Quinidine 
was prescribed as quinidine gluconate or sulfate 3 to 4 
times daily for a total average dose of 1.14 g (range 0.6 
to 2.6). The average daily dose of procainamide was 2.0 
g (range 0.75 to 3.0) administered every 4 to 6 hours. 
Digoxin was prescribed in a dose of 0.125 or 0.25 mg. 
Blood concentrations of the drugs were not obtained. 
The cumulative mortality graphs for antiarrhythmic 
agents were based on assignment of antiarrhythmic 
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drug at the time of discharge. The survival distributions 
of the 3 treatment groups overall and within digoxin 
status categories were calculated using the product-limit 
method and compared using the log rank test.8*9 The 
Cox-Breslow life table procedure, as implemented in the 
BMDP series, was used to examine the importance of 
possible covariates.lO 
RESULTS 
Characteristics of study patients are listed in Table 
I. Patients were classified at the time of discharge into 6 
groups based on the prescription of quinidine and pro- 
cainamide and whether or not digoxin therapy was used 
in each of these groups. 
When the patients prescribed digoxin were com- 
pared to those who were not, a significant (p <O.OOl) 
difference was observed in some factors. Patients pre- 
scribed digoxin were older (65 vs 60 years), and had an 
increased incidence of previous myocardial infarction, 
pulmonary congestion and diuretic intake. The antiar- 
rhythmic prescription, however, was not significantly 
different. At the 3-month follow-up visit, 96.4% of those 
prescribed quinidine and 92.3% of those prescribed pro- 
cainamide were still taking their original drug. At 6 
months, 76.7% and 78.6%, respectively, of patients con- 
tinued with their initial drug therapy. 
When concomitant digoxin therapy was disregarded, 
cumulative total (Figure 1) and sudden death (Figure 
2) survival rates were significantly lower for patients 
treated with procainamide and quinidiie, compared to 
those who did not receive these drugs. The 2-year cu- 
mulative total survival rates (Figure 1) for quinidine, 
procainamide and no therapy were 61, 57 and 71%, re 
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rates (Figure 2) for the quinidine, procainamide and no 
therapy groups were 69, 69 and 89%, respectively (p 
<O.Ol). 
The effect of the concomitant use of digoxin with the 
antiarrhythmic agents on the total survival was not as- 
sociated with a statistically significant difference be- 
tween the 3 antiarrhythmic treatment groups (Figure 
3). Patients receiving digoxin, however, generally had a 
worse total survival rate. The 2-year cumulative survival 
rates for quinidine, procainamide and no therapy groups 
in patients not receiving digoxin (Figure 3A) were 75, 
63 and 79%, respectively (p = 0.16), and in patients 
receiving digoxin (Figure 3B) were 43, 51 and 61%, re- 
spectively (p = 0.19). 
When sudden death survival (Figure 4) was exam- 
ined, both quinidine- and procainamide-treated patients 
experienced a worse sudden death survival rate com- 
FIGURE 4. cum&tivosuddondeothsur- 
vival for petionb not redving dkoxin (A) 
andthosoroceivingdigoxin(B). 
pared to the no treatment group, regardless of concur- 
rent digoxin therapy. The 2-year sudden death survival 
rates for quinidine, procainamide and no therapy groups 
in patients not receiving digoxin (Figure 4A) were 79, 
63 and 91%, respectively (p <0.05), and in patients re- 
ceiving digoxin were 57, 76 and 88%, respectively (p 
<0.05). 
While the relation of digoxin and antiarrhythmic 
therapy to worse survival seems clear when examined 
univariately, given the design of the study and the 
mechanism for assigning treatment, it is possible that 
they are not the only predictors of survival. This is indi- 
cated by the association of digoxin therapy with various 
other factors such as age and previous myocardial in- 
farction (Table I). Using a stepwise model building pro- 
cedure, the predictive value of age, previous myocardial 
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TABLE I Distribution of Clinical and Historical Events in Relation to Therapy at Discharge 
No Digoxin 
None 
(‘n = 19) 
Q Both 
(n = 64) (n = 25) (n = 108) 
Mean (yrs) age 59 59 61 60* 
History (%) 
Angina 47 74 60 55 
Heart failure 72 58 52 65’ 
Hypertension 47 37 36 43 
Previous MI 25 63 36 340 
Hospital course (%) 
Acute MI 50 37 40 45 
PC 55 32 32 45 
Medications at discharge (%) 
Other antiarrhythmics 0 5 0 1 
Diuretics 19 21 16 198 
Propranolol 13 5 4 9 
* p <OS01 no digoxin vs dioxin group. 
MI = myocardial infarction; P = procainamide; PC = pulmonary congestion by x-ray; Q = quinidine. 
Digoxin 
None 
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in and antiarrhythmic status, was considered for both 
overall survival and sudden death survival. The stron- 
gest predictors of death were age and previous myocar- 
dial infarction, while the strongest predictors for sudden 
death were age, treatment with an antiarrhythmic agent 
and previous myocardial infarction. These results indi- 
cate that antiarrhythmic therapy is related to worse sur- 
vival. However, with this study design it is difficult to 
determine if the poorer survival is related to the anti- 
arrhythmic drug itself or to additional factors. 
DISCUSSION 
It must be emphasized that this is a retrospective 
analysis of a very unique patient population in whom 
antiarrhythmic agents were administered empirically. It 
is not a randomized, controlled study of antiarrhythmic 
therapy in this population. Nevertheless, it does raise 
some important issues in regard to therapy of this high 
risk population. The choice of antiarrhythmic therapy 
was made by the practicing physician, who was un- 
aware of the results of the ambulatory electrocardio- 
gram. It is possible that physicians identified the high 
risk patient by other clinical characteristics and there- 
fore chose to initiate antiarrhythmic therapy. This could 
explain the higher mortality rate observed in the pa- 
tients prescribed antiarrhythmic therapy. With the ex- 
ception of baseline differences in patients receiving di- 
goxin, there were no consistent differences in regard to 
the administration of antiarrhythmic agents. The pre- 
scribed dosage of quinidine and procainamide was in 
the usual dose range and drug compliance is consistent 
with other antiarrhythmic trials. We observed in this 
analysis that patients who received no therapy appeared 
to fare the best, although this reached statistical signifi- 
cance only in the sudden death group. 
Our previous examination of predictors of death in 
resuscitated out-of-hospital cardiac arrest victims indi- 
cated that the history of digoxin therapy is associated 
with worse survival rate.3 This observation suggested 
that heart failure was a significant predictor of 
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subsequent death, and this has been supported by 
others.1,11-13 However, digoxin therapy, left ventricular 
dysfunction and ventricular ectopy are so closely inter- 
related that it is difficult to isolate the importance of 
each of these factors.13J4 The present analysis indicates 
that the use of digoxin was one of a number of multivar- 
iate predictors associated with an overall decreased total 
survival rate. 
Antiarrhythmic therapy in patients resuscitated af- 
ter a cardiac arrest has been generally considered advis- 
able, if not mandatory, since a high frequency of ven- 
tricular arrhythmia is associated with an accelerated 
mortality rate.3,7 The suggestion that antiarrhythmic 
therapy can be of benefit in this population has come 
from uncontrolled drug therapy directed by ambulatory 
electrocardiography or electrophysiologic studies. Using 
serial ambulatory electrocardiographic monitoring, the 
use of multiple antiarrhythmic agents in high risk pa- 
tients appeared to show a decreased mortality compared 
to historical controls.4 A major confounding variable, 
however, is the association of ventricular ectopy with 
left ventricular dysfunction. Arrhythmia suppression 
and the associated risks of therapy are adversely influ- 
enced by a decreased ejection fraction.‘J7J8 The Cardi- 
ac Arrhythmia Suppression Trial examined the effect of 
arrhythmia suppression on sudden death mortality.’ En- 
cainide and flecainide arms of the study were prema- 
turely stopped when an increased rate of arrhythmic 
death and total mortality was observed with those drugs 
compared to placebo. The sudden death rate at 1 year 
for patients with ejection fractions <30% was 9.5% with 
drugs and 3.6% with placebo. In patients with ejection 
fractions >30%, it was 3.7% and 0.8%, respectively. 
Balanced against the uncertain benefits of antiar- 
rhythmic therapy are the well-documented proarrhyth- 
mic effects of a number of these agents.’ 1,19-** Adverse 
reaction to antiarrhythmic agents is adversely affected 
by digoxin and diuretic therapy.19 These events are pre- 
sumed to occur early after the institution of drug thera- 
py, and were observed with almost all of the currently 
available agents.21 There was a tendency in this study 
for an accelerated mortality early after initiation 
of therapy but the survival curves continued to fall 
throughout the follow-up period, which is similar to the 
observations of the Cardiac Arrhythmia Suppression 
Trial. 
Although our data are applicable to a very unique 
group of patients with coronary artery disease, they also 
have important implications for patients with coronary 
artery disease in general, and they are consistent with 
recent studies.’ Our present observations suggest that 
empiric antiarrhythmic therapy with quinidine and pro- 
cainamide fails to provide protection in this high risk 
group. In each survival analysis, the patients who did 
not receive an antiarrhythmic agent fared better than 
those who were treated with these drugs, although this 
was statistically significant only in regard to sudden 
death. These observations should give us pause before 
embarking on empiric antiarrhythmic therapy in this 
high risk population. 
REFERENCES 
1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Prelimi- 
nary report: effect of encainide and flecainide on mortality in a randomized trial of 
arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 
406-412. 
2. Weaver W, Cobb L, Hallstrom A. Ambulatory arrhythmias in resuscitated 
victims of cardiac arrest. Circulation 1982,66:212-218. 
3. Goldstein S, Landis JR, Leighton R, Ritter G, Vasu CM, Wolfe RA, Acheson 
A, Medendorp SV. Predictive survival models for resuscitated victims of out-of- 
hospital cardiac arrest with coronary artery disease. Circuhtion 1985:71:873- 
880. 
4. Graboys TB, Lawn B, Podrid P. Long term survival of patients with malignant 
ventricular arrhythmias treated with antiarrhythmic drugs. Am J Cardiol 
1982;50:437-443. 
5. Wilber DJ, Garan H, Finkelstein D, Kelly E, Newell J, McGovern B, Ruskin 
JN. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the predic- 
6. Josephson ME, Horowitz LW, Spielman SR, Greenspan AM. Electrophysio- 
logic and hemodynamic studies in patients resuscitated from cardiac arrest. Am J 
Cardiol 1980;46:948-955, 
7. Temesy-Armos PN, Vanderbrug Medendorp S, Goldstein S, Landis JR, 
Leighton RF, Ritter G, Vasu CM, Wolfe RA, Acheson A. Predictive value of 
ventricular arrhythmias in resuscitated out-of-hospital cardiac arrest victims. Eur 
Heart J 1988,9:625-633. 
6. Kaplan EL, Meir P. Nonparametric estimation from incomplete observations. 
J Am Stat Assoc 1958;53:457-481. 
9. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R 
Stat Sot [A] 1972;135:185-198. 
10. Hopkins A. Survival analysis with covariates-Cox models. In: Dixon WJ, ed. 
BMDP Statistical Software. Berkeley, California: University ofCalifornia Press, 
1983576. 
Il. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients 
with ventricular tachyarrhythmias. N End J Med 1983;308:1436-1442. 
12. Moss AJ, Davis HT, Conrad DL, DeCamilla JJ, Odoroff CL. Digitalis- 
associated cardiac mortality after myocardial infarction. Circulation 1981; 
64:1150-1156. 
13. Multicenter Postinfarction Research Group. Risk stratification after myocar- 
dial infarction. N Engi J Med 1983;309:331-336. 
14. Byington R, Goldstein S. Association of digitalis therapy with mortality in 
survivors of acute myocardial infarction: observations in the Beta-Blocker Heart 
Attack Trial. JACC 1985;5:976-982. 
15. Peter T, Hamer A, Weiss D, Mandel WJ. Prognosis after stidden cardiac 
death without associated myocardial infarction: one year follow-up of empiric 
therapy with amiodarone. Am Heart J 1984;107:209-213. 
16. Rapaport E, Remedios P. The high risk patient after recovery from myocardi- 
al infarction: recognition and management. JACC 1983;1:391-400. 
17. Meissner MD, Kay HR, Horowitz LN, Spielman SR, Greenspan AM, 
Kutalek SP. Relation of acute antiarrhythmic drug efficacy to left ventricular 
function in coronary artery disease. Am J Cardiol 1988,61:/050-1055. 
16. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, 
Young JB. The inverse relationship between baseline left ventricular ejection 
fraction and outcome of antiarrbythmic therapy: a dangerous imbalance in the 
risk-benefit ratio. Am Heart J 1989;118:433-440. 
19. Minardo JD, Heger JJ. Miles WM, Zipes DP, Prystowsky EN. Clinical 
characteristics of patients with ventricular fibrillation during antiarrhythmic drug 
therapy. N Engl J Med 1988;319:257-262. 
20. Podrid PJ, Lampert S, Grayboys TB, Blatt CM, Low B. Aggravation of 
arrhythmia by antiarrhythmic drugs-incidence and predictors. Am J Cardiol 
1987;59:38E-44E. 
i~n~,fis:n86-n~4 
21. Stanton MS, Prystowsky EN, Fineberg NS, Miles WM. Zipies DP, Heger 
JJ. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients 
treated for ventricular tachycardia or fibrillation. JACC /989;14:209-215. 
22. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and 
provocation of ventricular arrhythmias by antiarrhythmic drugs. Circuhion 
tion of long-term outcome. N Eng/ J Med 1988;318:19-24. 
THE AMERICAN JOURNAL OF CARDIOLOGY MAY 15, 1990 1197 
